<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02883647</url>
  </required_header>
  <id_info>
    <org_study_id>PL</org_study_id>
    <nct_id>NCT02883647</nct_id>
  </id_info>
  <brief_title>Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b</brief_title>
  <official_title>Clinical Investigation About Therapeutic Effects and Long-term Follow-up After Ending Anti-hepatitis B Virus Therapy With Nucleos(t)Ide Analogs in Patients With Chronic Hepatitis b</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to observe the therapeutic effects and long-term follow-up after ending anti-HBV&#xD;
      therapy with nucleos(t)ide analogs in patients with chronic hepatitis b.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic hepatitis b were enrolled in the study. Age, sex, weight, height,&#xD;
      symptoms (e.g., fatigue, poor appetite, jaundice), relapse, retreatment, occurrence of liver&#xD;
      cirrhosis and hepatocellular carcinoma (HCC), mortality and survival rate were recorded in&#xD;
      the study. We also observed the laboratory tests including the levels of white blood cells&#xD;
      (WBC), red blood cells (RBC), hemoglobin (HGB), platelet (PLT), alanine transaminase (ALT),&#xD;
      aspartate transaminase (AST), total bilirubin (TBIL), blood urea nitrogen (BUN), creatine,&#xD;
      hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis B virus (HBV)&#xD;
      DNA, CD4 positive T lymphocyte (CD4+T), CD8 positive T lymphocyte (CD8+T), Type 1 helper T&#xD;
      lymphocyte (Th1), Type 2 helper T lymphocyte (Th2),fibroscan and B ultrasound. If clinical&#xD;
      relapse occurred, patients were retreated with nucleos(t)ide analogs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>relapse</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>non-relapse:serum HBV DNA &lt; 2000 IU/ml; virologic relapse: serum HBV DNA &gt; 2000 IU/ml; clinical relapse:serum HBV DNA &gt; 2000 IU/ml and ALT &gt; 2×ULN</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurence of cirrhosis and hepatocellular carcinoma</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>sign of cirrhosis and hepatocellular carcinoma through ultrasonography</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>retreatment</arm_group_label>
    <description>Patients with HBV DNA &gt; 2000 IU/ml and ALT ≥ 5×ULN;&#xD;
Patients with HBV DNA &gt; 2000 IU/ml and 2×ULN &lt; ALT ≤ 5×ULN, but have clinical symptoms.&#xD;
Intervention: Patients of this group will receive Entecavir 0.5mg/d or Tenofovir 300mg/d again.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-retreatment</arm_group_label>
    <description>Patients with HBV DNA ≤ 2000 IU/ml;&#xD;
Patients with HBV DNA &gt; 2000 IU/ml and ALT ≤ 2×ULN;&#xD;
Patients with HBV DNA &gt; 2000 IU/ml and 2×ULN &lt; ALT ≤ 5×ULN, but have no clinical symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir or Tenofovir</intervention_name>
    <description>Patients in retreatment group receive nucleos(t)ide analogs therapy (Entecavir 0.5mg/d or Tenofovir 300mg/d) again</description>
    <arm_group_label>retreatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients of chronic hepatitis b&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients received anti-HBV therapy with nucleos(t)ide analogs.&#xD;
&#xD;
          2. Last anti-HBV therapy should continue for at least 2 years.&#xD;
&#xD;
          3. For HBeAg positive patients, HBV DNA should keep negative for at least 1 year after&#xD;
             HBeAg seroconversion before the therapy ending; for HBeAg negative patients, HBV DNA&#xD;
             should keep negative for at least 2 years before the therapy ending.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Liver cirrhosis, HCC;&#xD;
&#xD;
          2. Patients with other factors causing active liver diseases;&#xD;
&#xD;
          3. Pregnancy or lactation;&#xD;
&#xD;
          4. Patients with HIV infection or congenital immune deficiency diseases;&#xD;
&#xD;
          5. Patients with severe diabetes, autoimmune diseases, other important organ dysfunctions&#xD;
             and other serious complications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Peng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenxiong Xu, Master</last_name>
    <phone>+8613760783281</phone>
    <email>xwx1983@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Peng, Doctor</last_name>
    <phone>+8613533978874</phone>
    <email>pzp33@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Peng, Doctor</last_name>
      <phone>+8613533978874</phone>
      <email>pzp33@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>August 24, 2016</last_update_submitted>
  <last_update_submitted_qc>August 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Liang Peng</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <keyword>chronic hepatitis b, nucleos(t)ide analog</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

